Estrogen receptor polymorphisms and the risk of endometrial cancer
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
- Pagani, Olivia, Gelber, Shari, Thürlimann, Beat, Fey, Martin F., Murray, Elizabeth, Forbes, John F., Coates, Alan S., Goldhirsch, Aron, Simoncini, Edda, Castiglione-Gertsch, Monica, Price, Karen N., Gelber, Richard D., Holmberg, Stig B., Crivellari, Diana, Collins, John, Lindtner, Jurij
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
- Rasmussen, Birgitte B., Regan, Meredith M., Braye, Stephen, Altermatt, Hans J., Gelber, Richard D., Castiglione-Gertsch, Monica, Goldhirsch, Aron, Gusterson, Barry A., Thürlimann, Beat, Coates, Alan S., Viale, Giuseppe, Lykkesfeldt, Anne E., Dell'Orto, Patrizia, Del Curto, Barbara, Henriksen, Katrine L., Mastropasqua, Mauro G., Price, Karen N., Méry, Eliane E., Lacroix-Triki, Magali
Are you sure you would like to clear your session, including search history and login status?